These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24371778)

  • 1. Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature.
    Poloni A; Costantini B; Mariani M; Leoni P
    Leuk Res Rep; 2013; 2(2):44-6. PubMed ID: 24371778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature.
    Allan RW
    Hematology; 2007 Dec; 12(6):493-6. PubMed ID: 17852444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
    Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
    Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes.
    Yoshida A; Zokumasu K; Wano Y; Yamauchi T; Imamura S; Takagi K; Kishi S; Urasaki Y; Tohyama K; Ueda T
    Haematologica; 2012 Sep; 97(9):1372-9. PubMed ID: 22419576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy-related myeloid neoplasms following treatment with radioiodine.
    Schroeder T; Kuendgen A; Kayser S; Kröger N; Braulke F; Platzbecker U; Klärner V; Zohren F; Haase D; Stadler M; Schlenk R; Czibere AG; Bruns I; Fenk R; Gattermann N; Haas R; Kobbe G; Germing U
    Haematologica; 2012 Feb; 97(2):206-12. PubMed ID: 21993688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
    Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
    Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports.
    Duarte FB; Lemes RPG; Dos Santos TEJ; Barbosa MC; de Vasconcelos JPL; Rocha-Filho FD; Zalcberg I; Coutinho D; Figueiredo MF; Carlos LB; de Vasconcelos PRL
    J Med Case Rep; 2017 May; 11(1):143. PubMed ID: 28527473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.
    Deschler B; Ihorst G; Platzbecker U; Germing U; März E; de Figuerido M; Fritzsche K; Haas P; Salih HR; Giagounidis A; Selleslag D; Labar B; de Witte T; Wijermans P; Lübbert M
    Haematologica; 2013 Feb; 98(2):208-16. PubMed ID: 22875615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.
    Thol F; Weissinger EM; Krauter J; Wagner K; Damm F; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Haematologica; 2010 Oct; 95(10):1668-74. PubMed ID: 20494930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.
    Ye D; Garcia-Manero G; Kantarjian HM; Xiao L; Vadhan-Raj S; Fernandez MH; Nguyen MH; Medeiros LJ; Bueso-Ramos CE
    J Hematop; 2009 Mar; 2(1):2-8. PubMed ID: 19669217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lymphocytic leukemia followed by myelodysplastic syndrome and erythroleukemia.
    Cazaceanu O; Iova A; Vladareanu AM; Onisai M; Enache C; Andrus E
    J Med Life; 2012; 5(Spec Issue):6-11. PubMed ID: 31803279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myelodysplastic syndromes--new treatment options].
    Germing U
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():123-6. PubMed ID: 16802536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.